TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

PIERRE FABRE

OncologyImmunologyGastroenterology
Specialty

PIERRE FABRE is a specialty pharmaceutical company focused on Oncology, Immunology, Gastroenterology.

1994
Since
2
Drugs
-
Trials
0
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

No recent activity
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 90%
1 drugs Phase 3: 1 Phase 2: 4 Phase 1: 9
Immunology 7%
0 drugs Phase 2: 1
Gastroenterology 3%
0 drugs Phase 1: 1

Pipeline Strength Pro

Loading...